 |
 |
what is an M.I? myocardial infarction? -----Original Message----- From: Dianne E. Cooperman Sent: Thursday, June 16, 2016 10:07 PM To: [log in to unmask] Subject: Re: PARKINSN Digest - 8 Jun 2016 to 10 Jun 2016 (#2016-103) Nick, My doctor at Georgetown university Hospital's movement Disorders Center of Excellence is the P.I. for the trial of Tasigna/Nilotinib. I was supposed to participate in the next phase, but he has advised me to wait until they accumulate another year's worth of safety data first. Apparently one of the Phase 1 study patients has had a M.I. It may not be related to the drug, of course, but I am willing to wait a year on that basis. Sudden death from M.I. Is the reason for the black box warning at the 800 mg/day dosage. That's all I know. Dianne Patient Dx in 2007 On Saturday, June 11, 2016, PARKINSN automatic digest system < [log in to unmask]> wrote: > There is 1 message totaling 25 lines in this issue. > > Topics of the day: > > 1. PARKINSN Digest - 7 Jun 2016 to 8 Jun 2016 (#2016-102) > > ---------------------------------------------------------------------- > > Date: Thu, 9 Jun 2016 18:53:21 -0700 > From: Nick <[log in to unmask] <javascript:;>> > Subject: Re: PARKINSN Digest - 7 Jun 2016 to 8 Jun 2016 (#2016-102) > > What issues has Tasigna had with parkies? Please be specific. What am I > wrong about? I am fully aware of the phase 1 trial, 11 parkies were > involved. I have talked to several of them, and they are all for > Tasigna. Tasigna is not DISAPPROVED for parkies. Tasigna is a valid > cross-label drug. > > How safer can it get! 9 years on the market for cancer patients at much > higher doses than used in the phase 1 trial. I could buy it in the USA > if I wanted to pay the obscenely high price that Novartis is charging > per pill. It is 40% cheaper in Mexico and India. It is 30% cheaper in > Canada. > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto: > [log in to unmask] <javascript:;> > In the body of the message put: signoff parkinsn > > ------------------------------ > > End of PARKINSN Digest - 8 Jun 2016 to 10 Jun 2016 (#2016-103) > ************************************************************** > -- Sent from Gmail Mobile ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn